MEDLINE Search Strategy
1. (review or review, tutorial or review, academic).pt.
2. (medline or medlars or embase or pubmed or cochrane).tw,sh.
3. (scisearch or psychinfo or psycinfo).tw,sh.
4. (psychlit or psyclit).tw,sh.
5. cinahl.tw,sh.
6. ((hand adj2 search$) or (manual$ adj2 search$)).tw,sh.
7. (electronic database$ or bibliographic database$ or computeri?ed database$ or online database$).tw,sh.
8. (pooling or pooled or mantel haenszel).tw,sh.
9. (peto or dersimonian or der simonian or fixed effect).tw,sh.
10. (retraction of publication or retracted publication).pt.
11. or/2-10
12. 1 and 11
13. meta-analysis.pt.
14. meta-analysis.sh.
15. (meta-analys$ or meta analys$ or metaanalys$).tw,sh.
16. (systematic adj5 review$).tw,sh.
17. (systematic adj5 overview$).tw,sh.
18. (quantitativ$ adj5 review$).tw,sh.
19. (quantitativ$ adj5 overview$).tw,sh.
20. (quantitativ$ adj5 synthesis$).tw,sh.
21. (methodologic$ adj5 review$).tw,sh.
22. (methodologic$ adj5 overview$).tw,sh.
23. (intergrative research review$ or research integration).tw.
24. or/13-23
25. 12 or 24
26. "randomized controlled trial".pt.
27. (random$ or placebo$ or single blind$ or double blind$ or triple blind$).ti,ab.
28. (retraction of publication or retracted publication).pt.
29. or/26-28
30. (animals not humans).sh.
31. ((comment or editorial or meta-analysis or practice-guideline or review or letter or journal correspondence) not "randomized controlled trial").pt.
32. (random sampl$ or random digit$ or random effect$ or random survey or random regression).ti,ab. not "randomized controlled trial".pt.
33. 29 not (30 or 31 or 32)
34. ((oral or direct) adj3 thrombin inhibitor$).ti,ab.
35. ((factor$ or antifactor$) adj3 (Xa inhibitor$ or drug$)).ti,ab.
36. (edoxaban or lixiana).ti,ab.
37. DU176b.mp.
38. 36 or 37
39. (apixaban or eliquis).ti,ab.
40. BMS-562247-01.mp.
41. (dabigatran or pradaxa or pradax or prazaxa).ti,ab.
42. EC3-4-21-5.mp.
43. (rivaroxaban or xarelto).ti,ab.
44. BAY59-7939.mp.
45. or/34-44
46. 45 and 25
47. 45 and 33
48. exp cohort studies/
49. cohort$.tw.
50. controlled clinical trial.pt.
51. epidemiologic methods/
52. limit 51 to yr=1966-1989
53. exp case-control studies/
54. (case$ and control$).tw.
55. or/48-50,52-54
56. 45 and 55
57. (ae or si or to or co).fs.
58. (safe or safety).ti,ab.
59. side effect$.ti,ab.
60. ((adverse or undesirable or harm$ or serious or toxic) adj3 (effect$ or reaction$ or event$ or outcome$)).ti,ab.
61. exp product surveillance, postmarketing/
62. exp adverse drug reaction reporting systems/
63. exp clinical trials, phase iv/
64. exp poisoning/
65. exp substance-related disorders/
66. exp drug toxicity/
67. exp abnormalities, drug induced/
68. exp drug monitoring/
69. exp drug hypersensitivity/
70. (toxicity or complication$ or noxious or tolerability).ti,ab.
71. exp Postoperative Complications/
72. exp Intraoperative Complications/
73. or/57-72
74. or/36-44
75. (73 and 74) not (56 or 46 or 47)
Embase Search Strategy
1. exp review/
2. (literature adj3 review$).ti,ab.
3. exp meta analysis/
4. exp "Systematic Review"/
5. or/1-4
6. (medline or medlars or embase or pubmed or cinahl or amed or psychlit or psyclit or psychinfo or psycinfo or scisearch or cochrane).ti,ab.
7. RETRACTED ARTICLE/
8. 6 or 7
9. 5 and 8
10. (systematic$ adj2 (review$ or overview)).ti,ab.
11. (meta?anal$ or meta anal$ or meta-anal$ or metaanal$ or metanaly$).ti,ab.
12. 9 or 10 or 11
13. (random$ or placebo$ or single blind$ or double blind$ or triple blind$).ti,ab.
14. RETRACTED ARTICLE/
15. or/13-14
16. (animal$ not human$).sh,hw.
17. (book or conference paper or editorial or letter or review).pt. not exp randomized controlled trial/
18. (random sampl$ or random digit$ or random effect$ or random survey or random regression).ti,ab. not exp randomized controlled trial/
19. 15 not (16 or 17 or 18)
20. exp heart atrium fibrillation/
21. ((atrial or atrium or auricular) adj3 (fibrillat$ or flutter$)).ti,ab.
22. 20 or 21
23. exp dabigatran etexilate/ or exp dabigatran/
24. (dabigatran or pradaxa or pradax or prazaxa).ti,ab.
25. exp rivaroxaban/
26. (rivaroxaban or xarelto).ti,ab.
27. BAY59-7939.mp.
28. exp edoxaban/
29. (edoxaban or lixiana).mp.
30. DU176b.mp.
31. exp apixaban/
32. (apixaban or eliquis).mp.
33. BMS-562247-01.mp.
34. ((factor adj3 Xa) or (Xa adj3 inhibitor$) or (FXa adj3 inhibitor$)).mp.
35. exp thrombin inhibitor/
36. or/23-35
37. 36 and 12
38. 36 and 19
39. exp cohort analysis/
40. exp longitudinal study/
41. exp prospective study/
42. exp follow up/
43. cohort$.tw.
44. or/39-43
45. 36 and 44
46. 45 not (37 or 38)
47. (ae or si or to or co).fs.
48. (safe or safety).ti,ab.
49. side effect$.ti,ab.
50. ((adverse or undesirable or harm$ or serious or toxic) adj3 (effect$ or reaction$ or event$ or outcome$)).ti,ab.
51. exp adverse drug reaction/
52. exp drug toxicity/
53. exp intoxication/
54. exp drug safety/
55. exp drug monitoring/
56. exp drug hypersensitivity/
57. exp postmarketing surveillance/
58. exp drug surveillance program/
59. exp phase iv clinical trial/
60. (toxicity or complication$ or noxious or tolerability).ti,ab.
61. exp postoperative complication/
62. exp Peroperative Complication/
63. or/47-62
64. 36 and 63
65. 64 not (37 or 38 or 45)
66. 65 and 22
67. 46 and 22
68. or/23-33
69. 63 and 68
70. 69 not (37 or 38 or 45)
Wiley Cochrane Database of Systematic Reviews, Controlled Trials and Economic Analyses, DARE and Grey Literature
Broad search terms such as atrial fibrillation, anticoagulants, and the drug names dabigatran, rivaroxaban, edoxaban, and apixaban were used.

From: 7.3, Literature Search Strategy

Cover of Safety, Effectiveness, and Cost-Effectiveness of New Oral Anticoagulants Compared with Warfarin in Preventing Stroke and Other Cardiovascular Events in Patients with Atrial Fibrillation
Safety, Effectiveness, and Cost-Effectiveness of New Oral Anticoagulants Compared with Warfarin in Preventing Stroke and Other Cardiovascular Events in Patients with Atrial Fibrillation [Internet].
Wells G, Coyle D, Cameron C, et al.
Copyright © 2012 Canadian Collaborative for Drug Safety, Effectiveness and Network Meta-Analysis.

Except where otherwise noted, this work is distributed under the terms of a Creative Commons Attribution-NonCommercial- NoDerivatives 4.0 International licence (CC BY-NC-ND), a copy of which is available at http://creativecommons.org/licenses/by-nc-nd/4.0/

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.